Merck Sharp + Dohme Corp.

Opko Health, Inc.

Schering Corporation

Ashwin Umesh Rao

Anandan Palani

Xianhai Huang

Dong Xiao

Robert G Aslanian

Neng-Yang Shih

Sunil Paliwal

Cheng Wang

Xiao Chen

Hon-Chung Tsui

Ning Shao

Sapna S Shah

Kevin D McCormick

Ying Huang

Christopher W Boyce

Michelle Laci Wrobleski

Jun Qin

Li Dong

Brian Alexander McKittrick

Younong Yu

Salem Fevrier

Jie Wu

Michael Berlin

Hongjun Zhang

Pauline C Ting

Rongze Kuang

Jianhua Chao

Manuel De Lera Ruiz

Junying Zheng

Haiqun Tang

Walter Won

Joey Lee Methot

Phieng Siliphaivanh

Robert D Mazzola, Jr

Purakkattle J Biju

Peter Orth

John P Caldwell

Wei Zhou

Qin Jiang

Elizabeth Helen Kelley

Pawan Dhondi

Sylvia Joanna Degrado

Jolicia Polivina Gauuan

Andrew J Leyhane

Jared N Cumming

Sung-Sau So

Wen-Lian Wu

Zhicai Wu

Gerald Wayne Shipps, Jr

Hong Liu

Shawn P Walsh

John S Debenham

Derun Li

Alan W Hruza

Jing Su

Johannes H Voigt

Robert Jason Herr

Jayaram R Tagat

Brandon Mitsuo Taoka

Jacqueline D Hicks

Brent Whitehead

Kevin D Dykstra

Ping Lan

Jerry Andrew Taylor

Sathesh P Bhat

Xiaohua Huang

Henry M Vaccaro

Mary Ann Caplen

Rachel Nicola MacCoss

Markus Kristofer Dahlgren

Claire Lankin

Zhongxiang Sun

Andreas Verras

Hong Dong Chu

Lana Michele Rossiter

Matthew Lombardo

Revathi Reddy Katipally

William Colby Brown

Clifford Cheng

Qi Zeng

Xianfeng Sun

Youngong Yu

Amy McCracken

Brandon M Taoka

Tianyuan Zhang

Amy Bittner McCracken

Jonathan E Gable

Ying R Huang

Robert D Mazzola

Amy Bittner Mccracken

Brent R Whitehead

Amy Mccracken

Brian Mckittrick

Rachel N Maccoss

Kevin D Mccormick

Brian A Mckittrick

Pawan K Dhondi

Purakkattle Johny Biju

Joe Lee Method

Kevin D Mccormic

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

Factor XIIa inhibitors

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease

A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NKreceptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

[object Object]

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

The invention provides certain substituted isoquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.

Substituted isoquinolines as CRTH2 receptor modulators

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor. 

The present invention relates to novel quinoxaline compounds of Formula I: as Fatty Acid Binding Protein ('FABP') inhibitors, pharmaceutical compositions comprising the quinoxaline compounds and the use of the quinoxaline compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Substituted quinoxalines as inhibitors of fatty acid binding protein

NK1 antagonists

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators

Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators

The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. 

Bicyclic heterocyclic derivatives and methods of use thereof

A compound having the general structure shown in Formula I: or pharmaceutically acceptable salt and/or solvates thereof are useful in treating diseases or conditions mediated by NKreceptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

The present invention provides compounds of Formula (I):   pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

Nitrogen-containing heterocyclic compounds and methods of use thereof

Growing community of inventors

Avenel, NJ, United States of America

Ashwin Umesh Rao